Loading
People who eat more fibre appear to respond better to immunotherapy, while some probiotic supplements may do the opposite. A proper trial would settle it.
Observational data in melanoma associate higher dietary fibre intake with improved checkpoint response, and over-the-counter probiotic use with worse response, with supporting mouse experiments. Diet is a cheap, scalable and modifiable exposure but has never been tested randomly alongside checkpoint therapy with microbiome and immune endpoints. Adherence measurement, through stool short-chain fatty acids, makes a rigorous trial possible.
Shares Laurence Zitvogel, Capture diet, fibre and antibiotic exposure in every immunotherapy pivotal trial, Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No incentive to repurpose cheap drugs.
Shares No incentive to repurpose cheap drugs, MD Anderson Cancer Center, No one can predict who responds to immunotherapy, Melanoma.
Shares Laurence Zitvogel, Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No incentive to repurpose cheap drugs, Cold tumours and the immunosuppressive microenvironment, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy, Melanoma.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Melanoma, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy, Melanoma.